Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation

被引：0
|
作者：
Prelaj, A. [1 ]
Bottiglieri, A. [1 ]
Galli, E. [1 ]
Lo Russo, G. [1 ]
Ferrara, R. [1 ]
Galli, G. [1 ]
De Toma, A. [1 ]
Brambilla, M. [1 ]
Occhipinti, M. [1 ]
Manglaviti, S. [1 ]
Beninato, T. [1 ]
Zattarin, E. [1 ]
Apollonio, G. [1 ]
Ganzinelli, M. [1 ]
Gallucci, R. [1 ]
Di Mauro, R. M. [1 ]
de Braud, F. [1 ]
Torri, V. [2 ]
Garassino, M. C. C. [3 ]
Proto, C. [1 ]
机构：
[1] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol Dept, Milan, Italy
[2] IRCCS Mario Negri Inst, Dept Oncol, Milan, Italy
[3] Univ Chicago, Dept Hematol Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1841
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1236P
引用
收藏
页码：S976 / S977
页数：2
相关论文
共 50 条
  • [31] High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
    Le, X.
    Sun, S.
    Haura, E.
    Bertino, E.
    Baik, C.
    Mamdani, H.
    Leu, S.
    Thiagalingam, A.
    Kokhreidze, J.
    Lebel, F.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1084 - S1085
  • [32] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Elamin, Yasir Y.
    Robichaux, Jacqulyne P.
    Carter, Brett W.
    Altan, Mehmet
    Tran, Hai
    Gibbons, Don L.
    Heeke, Simon
    Fossella, Frank, V
    Lam, Vincent K.
    Le, Xiuning
    Negrao, Marcelo, V
    Nilsson, Monique B.
    Patel, Anisha
    Vijayan, R. S. K.
    Cross, Jason B.
    Zhang, Jianjun
    Byers, Lauren A.
    Lu, Charles
    Cascone, Tina
    Feng, Lei
    Luthra, Rajyalakshmi
    San Lucas, Francis A.
    Mantha, Geeta
    Routbort, Mark
    Blumenschein, George, Jr.
    Tsao, Anne S.
    Heymach, John, V
    CANCER CELL, 2022, 40 (07) : 754 - +
  • [33] Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2
    Cui, Yetong
    Wang, Ruonan
    Wei, Yujiao
    Hou, Fei
    Li, Haixi
    Jiang, Yurui
    Sun, Yue
    Fu, Shushu
    Zuo, Lina
    Wang, Xiaoji
    Li, Ming
    Li, Jinling
    Liu, Ning
    Zhang, Kun
    Wei, Mingming
    Yang, Guang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 81
  • [34] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC
    Angela Zupa
    Giulia Vita
    Matteo Landriscina
    Luciana Possidente
    Michele Aieta
    Alfredo Tartarone
    Giuseppina Improta
    Medical Oncology, 2012, 29 : 3198 - 3201
  • [35] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC
    Zupa, Angela
    Vita, Giulia
    Landriscina, Matteo
    Possidente, Luciana
    Aieta, Michele
    Tartarone, Alfredo
    Improta, Giuseppina
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3198 - 3201
  • [36] Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC
    Ou, Sai-Hong Ignatius
    Hong, Jin-Liern
    Christopoulos, Petros
    Lin, Huamao M.
    Vincent, Sylvie
    Churchill, Eric N.
    Soeda, Junpei
    Kazdal, Daniel
    Stenzinger, Albrecht
    Thomas, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 744 - 754
  • [37] Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion
    Morikawa, K.
    Kakinuma, K.
    Inoue, T.
    Mineshita, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S496 - S496
  • [38] Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Negrao, Marelo Vailati
    Routbort, Mark
    Roeck, Brent
    Li, Shuai
    Liu, Shengwu
    Chen, Ting
    Ahnert, Jordi Rodon
    Diao, Lixia
    Nilsson, Monique B.
    Zhang, Shuxing
    Yang, Zane
    Wang, Jing
    Meric-Bernstam, Funda
    Wong, Kwok-Kin
    Heymach, John V.
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study
    Le, Xiuning
    Goldman, Jonathan
    Clarke, Jeffrey
    Techekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois
    Socinski, Mark
    CANCER RESEARCH, 2020, 80 (16)
  • [40] The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC
    Elamin, Y.
    Robichaux, J.
    Lam, V.
    Tsao, A.
    Lu, C.
    Blumenschein, G.
    Kurie, J.
    Brahmer, J.
    Li, S.
    Chen, T.
    Estrada-Bernal, A.
    Truini, A.
    Nilsson, M.
    Le, A.
    Tan, Z.
    Zhang, S.
    Doebele, R.
    Politi, K.
    Yang, Z.
    Liu, S.
    Wong, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1776 - S1776
12345